Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.
Also called NCT03857256
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 263 participants
- Registry
-
NCT03857256
-
- Other papers using this trial's data
- Supplementation with a β-glucan tablet has no effect on hyperlipidemia: a randomized, placebo-controlled clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03857256. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-31 (actual); primary completion 2021-08-31 (actual). Results posted on 2024-01-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
- Acronym
- BetAvena
- Condition
- Hyperlipidemias
- Intervention (Drug)
- CP105F
- Intervention (Drug)
- Placebo
- Lead sponsor
- Montreal Heart Institute
- Collaborator
- Ceapro Inc.
- Collaborator
- The Montreal Health Innovations Coordinating Center (MHICC)
Record details
- Record id
cardio:ct-nct03857256- Content hash
fe7fc86246ca305cc79a10741dbc33d7267a39cffcfcc0e7554cb57a8b5c8d74